Sinopharm to acquire 60% stake in China National Scientific Instruments and Materials Co.

Sinopharm Group Co. Ltd. agreed to acquire a 60% equity interest in China National Scientific Instruments and Materials Co. Ltd. from its controlling shareholder for RMB 5.11 billion, to strengthen its medical device business.

“Sinopharm Group Co. Ltd. is pleased to announce that, on 11 July 2018, the Company and China National Pharmaceutical Group Co., Ltd. entered into the Asset Purchase Agreement.”ir.sinopharmgroup.com.cn

• 1 source
• ir.sinopharmgroup.com.cnCompany NewsJul 11, 2018

Summarized from public sources; check the original articles before acting on it.